Dogodan Therapeutics
Dogodan Therapeutics (DTI) is a biotechnology company focused on developing revolutionary new treatments for diseases with high unmet medical needs, such as cancer and respiratory indications. They are pioneering a novel approach by treating diseases as dysregulated biological networks, designing nucleic acid therapeutics to directly modulate gene expression at multiple loci. This contrasts with traditional single-target approaches, allowing DTI to test and develop combination therapies from the discovery phase. Their DTI Genomic Medicine Platform integrates protein and nucleic acid structural biology with genomics, molecular biology, bioinformatics, statistical genetics, and machine learning to create custom-designed macromolecular therapeutics. The company is initially focusing on lung cancers (adenocarcinoma and squamous cell carcinoma), uveal melanoma, mesothelioma, and genetic loci from GWAS studies for COPD and asthma, utilizing localized epigenetic remodeling.
Dogodan Therapeutics
Dogodan Therapeutics (DTI) is a biotechnology company focused on developing revolutionary new treatments for diseases with high unmet medical needs, such as cancer and respiratory indications. They are pioneering a novel approach by treating diseases as dysregulated biological networks, designing nucleic acid therapeutics to directly modulate gene expression at multiple loci. This contrasts with traditional single-target approaches, allowing DTI to test and develop combination therapies from the discovery phase. Their DTI Genomic Medicine Platform integrates protein and nucleic acid structural biology with genomics, molecular biology, bioinformatics, statistical genetics, and machine learning to create custom-designed macromolecular therapeutics. The company is initially focusing on lung cancers (adenocarcinoma and squamous cell carcinoma), uveal melanoma, mesothelioma, and genetic loci from GWAS studies for COPD and asthma, utilizing localized epigenetic remodeling.